Urge Urinary Incontinence

Summary

Introduction

Urge urinary incontinence (UUI) is a relatively common disorder which can affect all age groups but becomes increasingly prevalent with old age. Although several pharmacological therapies are available for treating this distressing condition, patients' reluctance to present to a physician and incorrect diagnosis of the different overactive bladder subtypes limit the potential of this market.

Scope

• Quantitative treatment data from 418 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
• Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line treatments for UUI
• Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin and solifenacin
• Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline

Highlights

• Although the prevalence of UUI in women is high, the potential of this market is limited by the reluctance of patients to present to a physician for treatment. Direct to consumer advertising, where available, has already increased awareness and presentation of this condition but other strategies are also required to assist in enlarging the market.
• In theory, UUI could be managed successfully by PCPs. However, there is little belief in their ability to correctly diagnose the subtypes of OAB and this lack of confidence is supported by inappropriate prescribing trends by PCPs. Methods to address diagnosis and treatment of UUI in the primary care setting should reflect the priorities of PCPs.
• Older treatments for UUI are associated with a number of unpleasant side effects, leaving significant unmet need in this market. Several new products have recently entered the market yet there is little perceived differentiation from existing treatments. Emphasizing the improved efficacy and side effect profiles is key to improving uptake.

Reasons to Purchase

• Forecast product sales by understanding key aspects of UUI epidemiology, diagnosis and treatment
• Gain a better understanding of the challenges facing current and future players in the UUI market
• Identify physicians key concerns in UUI including unmet needs and the attributes that physicians believe are desirable for future treatments

Contents

• This product has been designed for delivery in a slide pack format (PowerPoint).
• Please select the slide pack option from the download menu at the side of the page
• Introduction
• Scope of this report
• Research and analysis highlights
• Key reasons to read this report
• Appendix A
  • Research methodology
  • Physician Sample breakdown
  • Urinary Incontinence and Overactive Bladder Insight Study - Physician Questionnaire
  • Section One Overview of Urinary Incontinence and overactive Bladder
  • Epidemiology
  • Presentation
  • Diagnosis
  • Referral pattern
  • Section Two Stress Urinary Incontinence
  • Diagnosis and treatment of SUI
  • Non-pharmacological treatment
  • Pharmacological treatment for SUI
  • Section Three Overactive Bladder With Urge Symptoms and/or Incontinence
  • Diagnosis and treatment of UUI
  • Pharmacological treatment for UUI
  • Diagnosis and treatment of 'dry OAB'
  • Pharmacological treatment for dry OAB
  • Section Four Mixed Stress/Urge Urinary Incontinence
  • Diagnosis and treatment of mixed SUI/UUI
  • Non-pharmacological treatment
  • Pharmacological treatment for mixed SUI/UUI
  • Section Five Interstitial Cystitis
  • Diagnosis and treatment of IC
  • Pharmacological treatment for IC
  • Section Six Drug Profiles
  • Section A: Drug influences on physicians' choice
  • Section B: The general treatment of urinary incontinence and overactive bladder
  • Contributing experts
  • US
  • Japan
  • Europe
• Appendix B
  • About Datamonitor
  • About Datamonitor Healthcare
  • About the CNS analysis team
  • Disclaimer